Dinutuximab Beta at the HUS and the Toulouse Oncopole
In this study the investigators wish to describe the cohort of pediatric patients suffering from neuroblastoma and treated with Dinutuximab and to compare the costs and quality of life between the two French centers, the University Hospital of Strasbourg (HUS) and the Oncopole of Toulouse.
- EligibilityCriteria: Inclusion Criteria:  Subjects aged 2 years to 25 years Male or female gender Subjects suffering from neuroblastoma and treated at the HUS or at the Oncopole center in Toulouse during the period from January 1, 1998 to December 31, 2023. Subject (and/or holders of parental authority) not opposing, after information, the reuse of the child's data for the purposes of this research and agreeing to respond to the quality of life survey.  Exclusion Criteria:  Patient or parents of the minor having expressed their opposition to participating in the study. specific clinical forms of the disease, interfering treatments and associated diseases. - Gender: All - MinimumAge: 2 Years - MaximumAge: 25 Years - StdAgeList: Child, Adult - StudyPopulation: Subjects aged 2 years to 25 years suffering from neuroblastoma and treated at the HUS or at the Oncopole center in Toulouse during the period from January 1, 1998 to December 31, 2023. - SamplingMethod: Probability Sample